Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517951 | 1.00 | MMP2 (0.33) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL24169092 | 0.97 | MMP2 (0.32) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL30171401 | 0.97 | MMP2 (0.32) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL575842 | 0.96 | ALDH1A1 (0.31) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL14966771 | 0.89 | MMP2 (0.31) | MMP2MMP8 | |
| SCHEMBL11876473 | 0.88 | — | — | |
| SCHEMBL7518057 | 0.84 | MMP2 (0.30) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL24865103 | 0.84 | EPHX1 (0.39) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL23435064 | 0.80 | — | — | |
| SCHEMBL25358318 | 0.78 | TSHR (0.38) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040167018-A1 | Palladium catalysts | VAN DER SCHAAF PAUL ADRIAAN (CH) | 2004-08-26 | — | — | US | claimed |
| EP-1414566-A1 | PALLADIUM CATALYSTS | Ciba SC Holding AG (CH) | 2004-05-06 | — | — | EP | claimed |
| WO-2003013723-A1 | PALLADIUM CATALYSTS | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2003-02-20 | — | — | WO | claimed |
| US-20040167018-A1 | Palladium catalysts | VAN DER SCHAAF PAUL ADRIAAN (CH) | 2004-08-26 | — | — | US | disclosed |
| EP-1414566-A1 | PALLADIUM CATALYSTS | Ciba SC Holding AG (CH) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003013723-A1 | PALLADIUM CATALYSTS | CIBA SPECIALITY CHEMICALS HOLDING INC. (CH) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167018-A1 | Palladium catalysts | PDCD1LG2, CD274, MT-CO3 | MMP2 4757/4885CA12 1425/4885CA1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.